東華大學圖書館 |

語系: 繁體中文

說明(常見問題)

回圖書館首頁

手機版館藏查詢

登入

回首頁

切換: 標籤 | MARC模式 | ISBD

The T cell co-stimulatory molecule G...

University of Toronto (Canada)., Immunology.

FindBook

Google Book

Amazon

博客來

The T cell co-stimulatory molecule GITR in the control and treatment of a persistent viral infection.

紀錄類型:	書目-電子資源 : Monograph/item
正題名/作者:	The T cell co-stimulatory molecule GITR in the control and treatment of a persistent viral infection./
作者:	Clouthier, Derek Leonard.
面頁冊數:	178 p.
附註:	Source: Dissertation Abstracts International, Volume: 77-06(E), Section: B.
Contained By:	Dissertation Abstracts International77-06B(E).
標題:	Immunology. -
電子資源:	http://pqdd.sinica.edu.tw/twdaoapp/servlet/advanced?query=3746259
ISBN:	9781339395364

The T cell co-stimulatory molecule GITR in the control and treatment of a persistent viral infection.
Clouthier, Derek Leonard.

The T cell co-stimulatory molecule GITR in the control and treatment of a persistent viral infection. - 178 p.

Source: Dissertation Abstracts International, Volume: 77-06(E), Section: B.

Thesis (Ph.D.)--University of Toronto (Canada), 2015.

During persistent viral infections such as human immunodeficiency virus (HIV) in human or lymphocytic choriomeningitis virus (LCMV) in mice, the immune response must achieve a balance between immune control and pathology. CD4 T cell help and co-stimulatory factors remain under-investigated in this context. This thesis explores the role of the Glucocorticoid-Induced Tumour Necrosis Factor Receptor-Related Protein (GITR) and its efficacy as a target for therapy in chronic infection. Mice that lack the T cell co-stimulatory molecule GITR have impaired LCMV-specific CD8 T cell responses and control of chronic LCMV infection. The effects of GITR were lost when mice were depleted of CD4 T cells. GITR directly supports the accumulation of IL-2+ T helper type 1 (Th1) cells, thereby indirectly facilitating early LCMV-specific CD8 T cell responses, late B cell responses, and viral control. In vivo GITR-induced signals were detected at day 3 post-infection, and defects in CD4 T cell accumulation in GITR-deficient T cells were apparent starting at day 5 post-infection. GITR-Ligand (GITRL) is maximally induced on antigen presenting cells at day 2 post-infection, but is downregulated to below baseline levels by day 8 post-infection, and remains so at the chronic stage of infection (day 21 post-infection). GITR expression was highest on regulatory T cells (Tregs) but was also detected on Th1 and LCMV-specific CD8 T cells at day 8 post-infection and was maintained at low levels at day 21 post-infection. As GITRL was limiting at this late time point, we investigated the potential of therapeutic stimulation of GITR using an anti-GITR agonist monoclonal antibody. Anti-GITR treatment at day 21 post-infection increased the frequency and number of LCMV-specific CD8 T cells and improved viral control. These effects of anti-GITR were CD8 T cell-intrinsic. Taken together, this thesis demonstrates that GITR plays an important early role on CD4 T cells to support CD8 T and B cell responses to persistent LCMV infection, but at later time points, anti-GITR therapy acts directly on the CD8 T cells to improve viral control. These studies may inform the development of novel immune therapies for human persistent viral infections as well as malignancies.

ISBN: 9781339395364Subjects--Topical Terms:

611031
Immunology.

The T cell co-stimulatory molecule GITR in the control and treatment of a persistent viral infection.
LDR:03207nmm a2200301 4500 001 2077700
005 20161114130344.5
008 170521s2015 ||||||||||||||||| ||eng d
020 $a 9781339395364
035 $a (MiAaPQ)AAI3746259
035 $a AAI3746259
040 $a MiAaPQ $c MiAaPQ
100 1 $a Clouthier, Derek Leonard. $3 3193228
245 1 4 $a The T cell co-stimulatory molecule GITR in the control and treatment of a persistent viral infection.
300 $a 178 p.
500 $a Source: Dissertation Abstracts International, Volume: 77-06(E), Section: B.
500 $a Adviser: Tania H. Watts.
502 $a Thesis (Ph.D.)--University of Toronto (Canada), 2015.
520 $a During persistent viral infections such as human immunodeficiency virus (HIV) in human or lymphocytic choriomeningitis virus (LCMV) in mice, the immune response must achieve a balance between immune control and pathology. CD4 T cell help and co-stimulatory factors remain under-investigated in this context. This thesis explores the role of the Glucocorticoid-Induced Tumour Necrosis Factor Receptor-Related Protein (GITR) and its efficacy as a target for therapy in chronic infection. Mice that lack the T cell co-stimulatory molecule GITR have impaired LCMV-specific CD8 T cell responses and control of chronic LCMV infection. The effects of GITR were lost when mice were depleted of CD4 T cells. GITR directly supports the accumulation of IL-2+ T helper type 1 (Th1) cells, thereby indirectly facilitating early LCMV-specific CD8 T cell responses, late B cell responses, and viral control. In vivo GITR-induced signals were detected at day 3 post-infection, and defects in CD4 T cell accumulation in GITR-deficient T cells were apparent starting at day 5 post-infection. GITR-Ligand (GITRL) is maximally induced on antigen presenting cells at day 2 post-infection, but is downregulated to below baseline levels by day 8 post-infection, and remains so at the chronic stage of infection (day 21 post-infection). GITR expression was highest on regulatory T cells (Tregs) but was also detected on Th1 and LCMV-specific CD8 T cells at day 8 post-infection and was maintained at low levels at day 21 post-infection. As GITRL was limiting at this late time point, we investigated the potential of therapeutic stimulation of GITR using an anti-GITR agonist monoclonal antibody. Anti-GITR treatment at day 21 post-infection increased the frequency and number of LCMV-specific CD8 T cells and improved viral control. These effects of anti-GITR were CD8 T cell-intrinsic. Taken together, this thesis demonstrates that GITR plays an important early role on CD4 T cells to support CD8 T and B cell responses to persistent LCMV infection, but at later time points, anti-GITR therapy acts directly on the CD8 T cells to improve viral control. These studies may inform the development of novel immune therapies for human persistent viral infections as well as malignancies.
590 $a School code: 0779.
650 4 $a Immunology. $3 611031
650 4 $a Molecular biology. $3 517296
650 4 $a Cellular biology. $3 3172791
650 4 $a Oncology. $3 751006
690 $a 0982
690 $a 0307
690 $a 0379
690 $a 0992
710 2 $a University of Toronto (Canada). $b Immunology. $3 3193210
773 0 $t Dissertation Abstracts International $g 77-06B(E).
790 $a 0779
791 $a Ph.D.
792 $a 2015
793 $a English
856 4 0 $u http://pqdd.sinica.edu.tw/twdaoapp/servlet/advanced?query=3746259